

## WHEN BREASTFEEDING MOTHERS NEED CNS-ACTING DRUGS

Evelyn T. Rubin, Amy Lee, Shinya Ito

The Division of Clinical Pharmacology and Toxicology, Department of Pediatrics. The Hospital for Sick Children, University of Toronto

Corresponding Author: [shinya.ito@sickkids.ca](mailto:shinya.ito@sickkids.ca)

---

### ABSTRACT

#### Background

Breastfeeding is the ideal method of infant nutrition. However, if mothers need medications such as the central nervous system (CNS) acting drugs, infant safety concerns arise. Summarized information on infant exposure levels to drugs in milk and associated side effect profiles will help clinicians to rationalize and justify important drug therapy for a breastfeeding patient.

#### Methods

Electronic searches of MEDLINE and PsycINFO from 1966-2003, and of EMBASE from 1980-2003, were conducted for studies on breastfeeding or breast milk and medications in the following categories: antidepressants, antipsychotics, antiepileptics (or anticonvulsants) and anxiolytics. The infant exposure level (%) was defined as follows:  $[\text{Drug concentration in milk (mg/mL)}] \times [\text{Daily milk intake (mL/kg/d)}] \times 100 / \text{Maternal dose (mg/kg/d)}$ .

#### Results

A total of 129 papers were eligible for analyses. Our findings indicate that the majority of the CNS-acting drugs, if taken by nursing women, result in average exposure levels to their breast-fed infants of less than 10% of the therapeutic doses per kg body weight. Exceptions are lithium, ethosuximide, phenobarbital, primidone, lamotrigine and topiramate. Adverse effect profiles do not always correlate with a higher exposure level. Overall, most reported adverse effect profiles appear benign. Where adverse effects were reported, they were often confounded by intrauterine exposure.

#### Conclusions

CNS-acting drugs taken by the mother do not appear to pose any major risks of immediate adverse effects to the breastfeeding infant, although with most of the newer drugs further research is needed to be conclusive.

*Key Words: Breastfeeding, breast milk, CNS-acting drugs, psychotropic drugs, exposure levels, adverse drug reactions*

---

**B**reastfeeding is the ideal method of infant nutrition. Exclusive breastfeeding for the first six months of life is strongly encouraged.<sup>1,2</sup> The many benefits of breastfeeding in infants include a decreased risk of diarrhea, otitis media, urinary tract infections, and necrotizing enterocolitis. Reduced incidence of inflammatory bowel disease and type I diabetes mellitus, and

higher cognitive neurodevelopment are also reported in breast-fed infants.

A recent survey showed approximately 80% of Canadian women initiated breastfeeding.<sup>3</sup> However, if mothers need medications, safety concerns arise. Although almost all drugs are excreted in milk, there are only a few absolute contraindications to breastfeeding, and cessation

of breastfeeding is rarely required.<sup>4,5</sup> Drugs are excreted into milk by passive diffusion and carrier-mediated processes.<sup>6</sup> The amount of drug excreted in breast milk depends on its pharmacokinetic factors, including ionization, plasma protein binding, molecular weight and lipophilicity. Drugs with a cationic nature, low plasma protein binding, low molecular weight, and high lipophilicity tend to be excreted into milk more than those without such characteristics.<sup>7</sup>

The amount of drug the breast-fed infant would ingest via milk per unit time is almost invariably lower than therapeutic doses for the infant, mostly around 1-10% of the infant therapeutic dose.<sup>5</sup> Such a low level exposure is unlikely to cause a dose-dependent effect.<sup>8</sup> However, these so-called "exposure levels" vary among drugs even in the same therapeutic category.<sup>9</sup> Information about infant exposure levels will help clinicians to rationalize and justify important drug therapy for a breastfeeding patient.

In addition, knowledge about adverse events in the breast-fed infants, and the number of the patient-infant pairs studied and reported in the medical literature will serve as a foundation of the clinical risk assessment. The central nervous system (CNS) acting drugs are among the most commonly queried medications during pregnancy and lactation.<sup>10</sup> However, safety information regarding these drugs for lactating women and their breast-fed infants has not been reviewed thoroughly, which makes clinical risk assessment difficult. In this article we will provide a quick reference for infant exposure levels to CNS-acting drugs in milk and a summary of reported adverse events.

## METHODS

Electronic searches of MEDLINE and PsycINFO were conducted from 1966-2003, and of EMBASE from 1980-2003. Original papers and review articles on breastfeeding or breast milk, and medications in the following categories: antidepressants, antipsychotics, antiepileptics (or anticonvulsants) and anxiolytics were queried.

Specific drug names were also queried along with either breastfeeding, breast milk or lactation. All articles of human studies involving the respective drugs, in the English or French

language were retrieved. Both infant exposure levels and adverse drug reactions in breast-fed infants were recorded.

The infant exposure level (%) was defined as follows:  $[\text{Drug concentration in milk (mg/mL)}] \times [\text{Daily milk intake (mL/kg/d)}] \times 100 / \text{Maternal dose (mg/kg/d)}$ .<sup>11</sup>

Our assumptions and operative procedures are as follows:

- a) a daily milk intake of 150mL/kg<sup>8</sup>,
- b) the highest reported drug concentration in milk for the patient was used in the calculations (i.e. worst-case analysis), and
- c) the mother's weight was assumed to be 65 kg wherever unreported.

All studies describing adverse events in the infant, or lack thereof, were used for adverse effect analyses. A study was excluded if the exposure was not at steady state. Review papers<sup>4,5,7,12-24</sup> were used for confirmation of calculations and sample size and for information on studies.

## RESULTS

Our MEDLINE search produced 345 original papers and review articles. A further analysis of references from review articles produced three papers published before 1966. Of the 348 articles, 123 papers were eligible for analyses: 11 for exposure level calculations only; 29 for adverse drug reaction information only, and 83 for both. We also identified 16 review papers. The EMBASE and PsycINFO searches produced an additional three papers. The majority of the CNS-acting drugs, if taken by nursing women, result in exposure levels in their breast-fed infants of less than 10% of the therapeutic doses per kg body weight (Table 1).

**TABLE I** Exposure Levels<sup>a</sup> and Summary of Adverse Drug Reactions in Nursing Infants of Mothers Treated with a CNS-acting Medication

Drugs	Exposure Level (% of the maternal dose on a body weight basis)					n/total <sup>c</sup>	Comments
	N <sup>b</sup>	<1 to <10	10 to <20	20 to <50	≥50		
<b>Antidepressants</b>							
<i>SSRIs</i>							
Citalopram* <sup>1-6</sup>	20					1/23	One infant was reported to have reversible, concentration dependent, uneasy sleep <sup>1</sup>
Fluoxetine* <sup>6-19</sup>	61					16/181	All infants except one with reported adverse events were also exposed in utero. Six patients had spontaneous resolution <sup>12</sup> , one infant on co-medications had transient seizure-like activity <sup>11</sup> , three had colic <sup>7,18</sup> , five had withdrawal symptoms <sup>7,12,18</sup> and one had lethargy, decreased nursing, moaning and unresponsiveness. <sup>16</sup>
Fluvoxamine <sup>6,20-26</sup>	6					0/16	
Paroxetine <sup>6,26-32</sup>	60					0/89	
Sertraline* <sup>6,26,33-40</sup>	36					1/138	One study <sup>32</sup> had a mean inconsistent with the others (n=11); we include it here for completion; One infant was reported to have benign neonatal sleep myoclonus which spontaneously resolved and was not considered by some reports to be an adverse reaction <sup>39</sup>
<b>Heterocyclics</b>							
Amitriptyline* <sup>41-46</sup>	6					0/5	
Amoxapine* <sup>47</sup>	1					NA	
Clomipramine <sup>45,46-48,49</sup>	3					0/8	
Desipramine* <sup>46,50</sup>	1					0/2	
Doxepin* <sup>51-53</sup>	3					2/3	One infant had poor suck and swallow, muscle hypotonia, vomiting, drowsiness and jaundice further to in utero exposure <sup>51</sup> . Another infant was pale, limp and drowsy with respiratory depression that resolved 24 hours after cessation of breast-feeding <sup>53</sup> .
Imipramine* <sup>45,46,54</sup>	5					0/19	
Maprotiline <sup>55</sup>	1					NA	
Nortriptyline <sup>46,56-59</sup>	1					0/22	
<b>Other</b>							
Bupropion* <sup>60,61</sup>	1					0/3	
Lithium <sup>62-66</sup>	14					1/14	ECG changes, a cyanotic episode and lethargy were reported within the first week of birth in an infant exposed in utero; symptoms resolved after cessation of lithium <sup>65</sup>
Nefazodone <sup>46,67,68</sup>	3					1/4	An infant was drowsy, lethargic, unable to maintain normal body weight and feeding poorly <sup>68</sup>
Venlafaxine* <sup>66,69-71</sup>	9					0/15	
<b>Antipsychotics</b>							
<i>Traditional</i>							
Chlorpromazine <sup>72,73</sup>	1					1/3	Drowsiness and lethargy in one infant; possible in utero exposure <sup>72</sup>
Chlorprothixene <sup>74</sup>	2					0/2	

When breastfeeding mothers need CNS-acting drugs

Haloperidol <sup>75-77</sup>	11					3/14	Three infants displayed delayed developmental scores following in utero exposure to both haloperidol and chlorpromazine <sup>75</sup>
Perphenazine <sup>78</sup>	1					0/1	
<b>Atypical</b>							
Clozapine <sup>79</sup>	1					NA	
Olanzapine <sup>80-82</sup>	12					0/14	
Risperidone* <sup>83</sup>	1					NA	
<b>Anxiolytics</b>							
Alprazolam <sup>84,85</sup>	NA					1/6	Irritability, sleep disturbances and withdrawal following in utero exposure <sup>85</sup> . One case of drowsiness reported by mother did not require medical attention and was not considered an adverse event <sup>84</sup>
Clonazepam <sup>86,87</sup>	1					1/2	Apnea (cyanosis, hypotonia, lethargy from in utero exposure); resolution at 10 days <sup>87</sup>
Diazepam* <sup>88-92</sup>	8					2/9	One reported case of lethargy and poor weight gain <sup>90</sup> and another case of sedation following in utero exposure <sup>91</sup> ; both cases were reversible
Oxazepam <sup>93</sup>	1					NA	
Lorazepam <sup>94</sup>	1					0/1	
Temazepam <sup>95</sup>	10					0/10	Calculated using the reported detection limits
<b>Antiepileptics</b>							
<b>First Generation</b>							
Carbamazepine <sup>11,96-105</sup>	29					11/31	All reported adverse reactions were secondary to in utero exposures or co-medications (mainly other antiepileptics). Transient cholestatic hepatitis seen in two infants <sup>96,97</sup> and transient seizure-like activity in one <sup>11</sup> . Hepatic dysfunction seen in one infant <sup>98</sup> ; weakness in suckling and poor feeding seen in four infants <sup>100,105</sup> ; hyperexcitability in two infants <sup>105</sup> ; drowsiness, irritability, refusal to feed and high-pitched cry in one <sup>105</sup>
Ethosuximide <sup>106-109</sup>	8					3/6	All infants exposed in utero and all but one to co-medications. Two cases of hyperexcitability and one case of sedation reported <sup>107</sup>
Phenobarbital* <sup>110-112</sup>	12					NA/17	Sedation in an unspecified number of infants exposed in utero to multiple medications <sup>110</sup>
Phenytoin <sup>86,113-115</sup>	9					1/9	Methemoglobinemia in one patient also on phenobarbital with in utero exposure <sup>115</sup>
Primidone* <sup>101,110,111</sup>	5					NA/12	Sedation and feeding problems in an unspecified number of infants exposed in utero to multiple medications <sup>110</sup>
Valproic Acid <sup>99,116-123</sup>	21					1/34	Reversible thrombocytopenia and anemia in one infant with in utero exposure <sup>117</sup>
<b>Second Generation</b>							
Gabapentin <sup>124</sup>	2					0/2	
Lamotrigine <sup>125-127</sup>	11					0/11	
Topiramate <sup>128</sup>	3					0/3	
Vigabatrin <sup>129</sup>	2					NA	

■ = level indicating the weighted mean

■ = level indicating the range of reported values

\* including active metabolite(s) NA indicates information unavailable

<sup>a</sup>Averages were calculated from studies meeting the inclusion criteria based on our assumptions (see methods). If no lighter shade is present, the mean fell in the same category as the entire range of values.

<sup>b</sup>Sample size of studies with exposure level information meeting inclusion criteria

<sup>c</sup>Number of infants with reported adverse events over total sample size of studies meeting inclusion criteria (includes studies which may not have available data for exposure level calculations)

## DISCUSSION

Unless the infant has a substantially reduced drug elimination capacity, the exposure would seldom reach even a therapeutic level. Indeed, infants are rarely found to achieve pharmacologically significant serum concentrations of the drug.

Exceptions are found in some of the antiepileptic agents such as phenobarbital, primidone and ethosuximide. These drugs may reach an exposure level of greater than 50%. This *per se* does not mean that the infant will be adversely affected. However, other antiepileptics with favorable pharmacological profiles would be preferred. Infant exposure levels to fluoxetine in milk are mostly below 10%, and reported adverse events are transient in nature. Although the clinical significance is unclear, one study suggested that weight gain of infants exposed to the drug in milk is smaller than in the non-exposed infants.<sup>25</sup> Lithium may achieve exposure levels >10%, but there is only one case report of an adverse event, which was confounded by intrauterine exposure.<sup>26</sup> In our clinical program in Toronto, we take an individualized approach based on monitoring of drug concentration in milk.<sup>27</sup> Overall, women can be allowed to continue breastfeeding while receiving these drugs.

Although antidepressants have been studied extensively, there is a shortage of data on the other categories of CNS-acting drugs. In particular, newer antipsychotics such as olanzapine and risperidone are being used more frequently and merit further analysis. IndentData on long-term effects of the low-level exposure to drugs via breastfeeding is scarce. Moreover, often-associated intrauterine exposures complicate the issue. Compared with intrauterine exposure to maternal drugs, which usually reaches the therapeutic level, drug exposure via breastfeeding is considered minimal for the majority of these drugs. Health professionals should clearly communicate this fact to breastfeeding patients.

Non-adherence to chronic medications such as antidepressants may cause serious consequences. Throughout pregnancy and the lactation period, women are understandably anxious about any uncertainty surrounding the safety of their medications to their infants.

Not infrequently, they stop the necessary medications to continue breastfeeding<sup>28</sup> or discontinue breastfeeding altogether.<sup>29,30</sup> The summary provided in Table 1 is intended to be a useful tool for practitioners for assessing infant exposure levels of CNS-acting drugs in breast milk and the adverse event risks, and help them provide information to lactating mothers.

## Acknowledgment

This study was supported in part by a CIHR grant.

## REFERENCES

1. American Academy of Pediatrics. Work Group on Breastfeeding. Breastfeeding and the use of human milk. *Pediatrics* 1997; 100(6):1035-1039.
2. Canadian Paediatric Society, Dietitians of Canada, Health Canada. Nutrition for Healthy Term Infants. [http://www.hc-sc.gc.ca/dca-dea/publications/pdf/infant\\_e.pdf](http://www.hc-sc.gc.ca/dca-dea/publications/pdf/infant_e.pdf). 1998. Minister of Public Works and Government Services, Ottawa.
3. Health Canada. Statistical Report on the Health of Canadians. 1999.
4. Anderson PO, Pochop SL, Manoguerra AS. Adverse drug reactions in breastfed infants: less than imagined. *Clin Pediatr (Phila)* 2003; 42(4):325-340.
5. Ito S. Drug therapy for breastfeeding women. *N Engl J Med* 2000; 343(2):118-126.
6. Ito S, Lee A. Drug excretion into breast milk-Overview. *Adv Drug Deliv Rev* 2003; 55(5):617-627.
7. Pons G, Rey E, Matheson I. Excretion of psychoactive drugs into breast milk. Pharmacokinetic principles and recommendations. *Clin Pharmacokinet* 1994; 27(4):270-289.
8. Bennett PN e. *Drugs and human lactation*. 2nd ed. 1996.
9. Ito S, Koren G. A novel index for expressing exposure of the infant to drugs in breast milk. *Br J Clin Pharmacol* 1994; 38(2):99-102.
10. Einarson A, Portnoi G, Koren G. Update on mother risk updates. Seven years of questions and answers. *Can Fam Physician* 2002; 48:1301-1304.
11. Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clinical pharmacokinetic considerations. *Clin Pharmacokinet* 1988; 14(4):217-240.
12. Burt VK, Suri R, Altshuler L, Stowe Z, Hendrick VC, Muntean E. The use of psychotropic medications during. *Am J Psychiatry* 2001; 158(7):1001-1009.
13. Hagg S, Spigset O. Anticonvulsant use during lactation. *Drug Saf* 2000; 22(6):425-440.

14. Bar-Oz B, Nulman I, Koren G, Ito S. Anticonvulsants and breast feeding: a critical review. *Paediatr Drugs* 2000; 2(2):113-126.
15. Tenyi T, Csabi G, Trixler M. Antipsychotics and breastfeeding: a review of the literature. *Paediatr Drugs* 2000; 2(1):23-28.
16. Spigset O, Hagg S. Excretion of Psychotropic Drugs into Breast Milk. *CNS Drugs* 1998; 9(2):111-134.
17. Misri S, Kostaras X. Benefits and risks to mother and infant of drug treatment for postnatal depression. *Drug Saf* 2002; 25(13):903-911.
18. Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding: a review. *J Clin Psychiatry* 2000; 61(2):79-90.
19. Crawford P. Epilepsy and pregnancy. *Seizure* 2002; 11 Suppl A:212-219.
20. Winans EA. Antipsychotics and breastfeeding. *J Hum Lact* 2001; 17(4):344-347.
21. Wisner KL, Perel JM, Findling RL. Antidepressant treatment during breastfeeding. *Am J Psychiatry* 1996; 153(9):1132-1137.
22. Llewellyn A, Stowe ZN. Psychotropic medications in lactation. *J Clin Psychiatry* 1998; 59 Suppl 2:41-52.
23. Hale TW. Medications in breastfeeding mothers of preterm infants. *Pediatr Ann* 2003; 32(5):337-347.
24. Transfer of drugs and other chemicals into human milk. *Pediatrics* 2001; 108(3):776-789.
25. Chambers CD, Anderson PO, Thomas RG, Dick LM, Felix RJ, Johnson KA et al. Weight gain in infants breastfed by mothers who take fluoxetine. *Pediatrics* 1999; 104(5):e6
26. Tunnessen WW, Jr., Hertz CG. Toxic effects of lithium in newborn infants: a commentary. *J Pediatr* 1972; 81(4):804-807.1.
27. Moretti ME, Koren G, Verjee Z, Ito S. Monitoring lithium in breast milk: an individualized approach for breastfeeding mothers. *Ther Drug Monit* 2003; 25(3):364-366.
28. Ito S, Koren G, Einarson TR. Maternal noncompliance with antibiotics during breastfeeding. *Ann Pharmacother* 1993; 27(1):40-42.
29. Lee A, Moretti ME, Collantes A, Chong D, Mazzotta P, Koren G et al. Choice of breastfeeding and physicians' advice: a cohort study of women receiving propylthiouracil. *Pediatrics* 2000; 106(1 Pt 1):27-30.
30. Ito S, Moretti M, Liao M, Koren G. Initiation and duration of breastfeeding in women receiving antiepileptics. *Am J Obstet Gynecol* 1995; 172(3):881-886.

#### TABLE 1 REFERENCES

1. Rampono J, Kristensen JH, Hackett LP, Paech M, Kohan R, Ilett KF. Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants. *Br J Clin Pharmacol* 2000; 50(3):263-268.
2. Jensen PN, Olesen OV, Bertelsen A, Linnet K. Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant. *Ther Drug Monit* 1997; 19(2):236-239.
3. Spigset O, Carieborg L, Ohman R, Norstrom A. Excretion of citalopram in breast milk. *Br J Clin Pharmacol* 1997; 44(3):295-298.
4. Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K. Citalopram in pregnancy and lactation. *Clin Pharmacol Ther* 2002; 72(2):184-191.
5. Hendrick V, Smith LM, Hwang S, Altshuler LL, Haynes D. Weight gain in breastfed infants of mothers taking antidepressant medications. *J Clin Psychiatry* 2003; 64(4):410-412.
6. Kristensen JH, Ilett KF, Hackett LP, Yapp P, Paech M, Begg EJ. Distribution and excretion of fluoxetine and norfluoxetine in human milk. *Br J Clin Pharmacol* 1999; 48(4):521-527.
7. Suri R, Stowe ZN, Hendrick V, Hostetter A, Widawski M, Altshuler LL. Estimates of nursing infant daily dose of fluoxetine through breast milk. *Biol Psychiatry* 2002; 52(5):446-451.
8. Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. *J Clin Pharmacol* 1996; 36(1):42-47.
9. Isenberg KE. Excretion of fluoxetine in human breast milk. *J Clin Psychiatry* 1990; 51(4):169.
10. Brent NB, Wisner KL. Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. *Clin Pediatr (Phila)* 1998; 37(1):41-44.
11. Moretti ME, Sharma A, Bar-Oz B, Koren G, Ito S. Fluoxetine and its effects on the nursing infant; a prospective cohort. *Clin Pharmacol Ther* 1999; 65(2):141.
12. Hendrick V, Stowe ZN, Altshuler LL, Mintz J, Hwang S, Hostetter A et al. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. *Biol Psychiatry* 2001; 50(10):775-782.
13. Yoshida K, Smith B, Craggs M, Kumar RC. Fluoxetine in breast-milk and developmental outcome of breast-fed infants. *Br J Psychiatry* 1998; 172:175-178.
14. Burch KJ, Wells BG. Fluoxetine/norfluoxetine concentrations in human milk. *Pediatrics* 1992; 89(4 Pt 1):676-677.

15. Hale TW, Shum S, Grossberg M. Fluoxetine toxicity in a breastfed infant. *Clin Pediatr (Phila)* 2001; 40(12):681-684.
16. Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. *Clin Pharmacol Ther* 2003; 73(4):330-337.
17. Lester BM, Cucca J, Andreozzi L, Flanagan P, Oh W. Possible association between fluoxetine hydrochloride and colic in an infant. *J Am Acad Child Adolesc Psychiatry* 1993; 32(6):1253-1255.
18. Chambers CD, Anderson PO, Thomas RG, Dick LM, Felix RJ, Johnson KA et al. Weight gain in infants breastfed by mothers who take fluoxetine. *Pediatrics* 1999; 104(5):e61.
19. Kristensen JH, Hackett LP, Kohan R, Paech M, Ilett KF. The amount of fluvoxamine in milk is unlikely to be a cause of adverse effects in breastfed infants. *J Hum Lact* 2002; 18(2):139-143.
20. Wright S, Dawling S, Ashford JJ. Excretion of fluvoxamine in breast milk. *Br J Clin Pharmacol* 1991; 31(2):209.
21. Hagg S, Granberg K, Carleborg L. Excretion of fluvoxamine into breast milk. *Br J Clin Pharmacol* 2000; 49(3):286-288.
22. Arnold LM, Suckow RF, Lichtenstein PK. Fluvoxamine concentrations in breast milk and in maternal and infant sera. *J Clin Psychopharmacol* 2000; 20(4):491-493.
23. Yoshida K, Smith B, Kumar RC. Fluvoxamine in breast-milk and infant development. *Br J Clin Pharmacol* 1997; 44(2):210-211.
24. Piontek CM, Wisner KL, Perel JM, Peindl KS. Serum fluvoxamine levels in breastfed infants. *J Clin Psychiatry* 2001; 62(2):111-113.
25. Hendrick V, Fukuchi A, Altshuler L, Widawski M, Wertheimer A, Brunhuber MV. Use of sertraline, paroxetine and fluvoxamine by nursing women. *Br J Psychiatry* 2001; 179:163-166.
26. Ohman R, Hagg S, Carleborg L, Spigset O. Excretion of paroxetine into breast milk. *J Clin Psychiatry* 1999; 60(8):519-523.
27. Stowe ZN, Cohen LS, Hostetter A, Ritchie JC, Owens MJ, Nemeroff CB. Paroxetine in human breast milk and nursing infants. *Am J Psychiatry* 2000; 157(2):185-189.
28. Begg EJ, Duffull SB, Saunders DA, Buttimore RC, Ilett KF, Hackett LP et al. Paroxetine in human milk. *Br J Clin Pharmacol* 1999; 48(2):142-147.
29. Spigset O, Carleborg L, Norstrom A, Sandlund M. Paroxetine level in breast milk. *J Clin Psychiatry* 1996; 57(1):39.
30. Misri S, Kim J, Riggs KW, Kostaras X. Paroxetine levels in postpartum depressed women, breast milk, and infant serum. *J Clin Psychiatry* 2000; 61(11):828-832.
31. Hendrick V, Stowe ZN, Altshuler LL, Hostetter A, Fukuchi A. Paroxetine use during breastfeeding. *J Clin Psychopharmacol* 2000; 20(5):587-589.
32. Stowe ZN, Hostetter AL, Owens MJ, Ritchie JC, Sternberg K, Cohen LS et al. The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. *J Clin Psychiatry* 2003; 64(1):73-80.
33. Epperson N, Czarkowski KA, Ward-O'Brien D, Weiss E, Gueorguieva R, Jatlow P et al. Maternal sertraline treatment and serotonin transport in breastfeeding mother-infant pairs. *Am J Psychiatry* 2001; 158(10):1631-1637.
34. Dodd S, Stocky A, Buist A, Burrows GD, Norman TR. Sertraline analysis in the plasma of breast-fed infants. *Aust N Z J Psychiatry* 2001; 35(4):545-546.
35. Kristensen JH, Ilett KF, Duscil LJ, Hackett LP, Yapp P, Wojnar-Horton RE et al. Distribution and excretion of sertraline and N-desmethylsertraline in human milk. *Br J Clin Pharmacol* 1998; 45(5):453-457.
36. Wisner KL, Perel JM, Blumer J. Serum sertraline and N-desmethylsertraline levels in breastfeeding mother-infant pairs. *Am J Psychiatry* 1998; 155(5):690-692.
37. Stowe ZN, Owens MJ, Landry JC, Kilts CD, Ely T, Llewellyn A et al. Sertraline and desmethylsertraline in human breast milk and nursing infants. *Am J Psychiatry* 1997; 154(9):1255-1260.
38. Mammen OK, Perel JM, Rudolph G, Foglia JP, Wheeler SB. Sertraline and norsesertraline levels in three breastfed infants. *J Clin Psychiatry* 1997; 58(3):100-103.
39. Altshuler LL, Burt VK, McMullen M, Hendrick V. Breastfeeding and sertraline: a 24-hour analysis. *J Clin Psychiatry* 1995; 56(6):243-245.
40. Breyer-Pfaff U, Nill K, Entenmann KN, Gaertner HJ. Secretion of amitriptyline and metabolites into breast milk. *Am J Psychiatry* 1995; 152(5):812-813.
41. Brixen-Rasmussen L, Halgrener J, Jorgensen A. Amitriptyline and nortriptyline excretion in human breast milk. *Psychopharmacology (Berl)* 1982; 76(1):94-95.
42. Bader TF, Newman K. Amitriptyline in human breast milk and the nursing infant's serum. *Am J Psychiatry* 1980; 137(7):855-856.
43. Pittard WB, III, O'Neal W, Jr. Amitriptyline excretion in human milk. *J Clin Psychopharmacol* 1986; 6(6):383-384.

44. Yoshida K, Smith B, Craggs M, Kumar RC. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. *J Affect Disord* 1997; 43(3):225-237.
45. Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. *Int J Psychiatry Med* 1991; 21(2):157-171.
46. Gelenberg AJ. Single case study. Amoxapine, a new antidepressant, appears in human milk. *J Nerv Ment Dis* 1979; 167(10):635-636.
47. Wisner KL, Perel JM, Foglia JP. Serum clomipramine and metabolite levels in four nursing mother-infant pairs. *J Clin Psychiatry* 1995; 56(1):17-20.
48. Schimmell MS, Katz EZ, Shaag Y, Pastuszak A, Koren G. Toxic neonatal effects following maternal clomipramine therapy. *J Toxicol Clin Toxicol* 1991; 29(4):479-484.
49. Stancer HC, Reed KL. Desipramine and 2-hydroxydesipramine in human breast milk and the nursing infant's serum. *Am J Psychiatry* 1986; 143(12):1597-1600.
50. Frey OR, Scheidt P, von Brenndorff AI. Adverse effects in a newborn infant breast-fed by a mother treated with doxepin. *Ann Pharmacother* 1999; 33(6):690-693.
51. Kemp J, Ilett KF, Booth J, Hackett LP. Excretion of doxepin and N-desmethyldoxepin in human milk. *Br J Clin Pharmacol* 1985; 20(5):497-499.
52. Matheson I, Pande H, Alertsens AR. Respiratory depression caused by N-desmethyldoxepin in breast milk. *Lancet* 1985; 2(8464):1124.
53. Sovner R, Orsulak PJ. Excretion of imipramine and desipramine in human breast milk. *Am J Psychiatry* 1979; 136(4A):451-452.
54. Lloyd AH. Practical considerations in the use of maprotiline (Ludiomil) in general practice. *J Int Med Res* 1977; 5 Suppl 4:122-138.
55. Wisner KL, Perel JM, Findling RL, Hinnes RL. Nortriptyline and its hydroxymetabolites in breastfeeding mothers and newborns. *Psychopharmacol Bull* 1997; 33(2):249-251.
56. Wisner KL, Perel JM. Nortriptyline treatment of breastfeeding women. *Am J Psychiatry* 1996; 153(2):295.
57. Wisner KL, Perel JM. Serum nortriptyline levels in nursing mothers and their infants. *Am J Psychiatry* 1991; 148(9):1234-1236.
58. Matheson I, Skjaeraasen J. Milk concentrations of flupenthixol, nortriptyline and zuclopenthixol and between-breast differences in two patients. *Eur J Clin Pharmacol* 1988; 35(2):217-220.
59. Baab SW, Peindl KS, Piontek CM, Wisner KL. Serum bupropion levels in 2 breastfeeding mother-infant pairs. *J Clin Psychiatry* 2002; 63(10):910-911.
60. Briggs GG, Samson JH, Ambrose PJ, Schroeder DH. Excretion of bupropion in breast milk. *Ann Pharmacother* 1993; 27(4):431-433.
61. Moretti ME, Koren G, Verjee Z, Ito S. Monitoring lithium in breast milk: an individualized approach for breastfeeding mothers. *Ther Drug Monit* 2003; 25(3):364-366.
62. Sykes PA, Quarrie J, Alexander FW. Lithium carbonate and breastfeeding. *Br Med J* 1976; 2(6047):1299.
63. Schou M, Amdisen A. Lithium and pregnancy. 3. Lithium ingestion by children breast-fed by women on lithium treatment. *Br Med J* 1973; 2(5859):138.
64. Tunnessen WW, Jr., Hertz CG. Toxic effects of lithium in newborn infants: a commentary. *J Pediatr* 1972; 81(4):804-807.
65. Weinstein MR, Goldfield M. Lithium carbonate treatment during pregnancy; report of a case. *Dis Nerv Syst* 1969; 30(12):828-832.
66. Dodd S, Maguire KP, Burrows GD, Norman TR. Nefazodone in the breast milk of nursing mothers: a report of two patients. *J Clin Psychopharmacol* 2000; 20(6):717-718.
67. Yapp P, Ilett KF, Kristensen JH, Hackett LP, Paech MJ, Rampono J. Drowsiness and poor feeding in a breast-fed infant: association with nefazodone and its metabolites. *Ann Pharmacother* 2000; 34(11):1269-1272.
68. Ilett KF, Kristensen JH, Hackett LP, Paech M, Kohan R, Rampono J. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants. *Br J Clin Pharmacol* 2002; 53(1):17-22.
69. Hendrick V, Altshuler L, Wertheimer A, Dunn WA. Venlafaxine and breastfeeding. *Am J Psychiatry* 2001; 158(12):2089-2090.
70. Ilett KF, Hackett LP, Dushi LJ, Roberts MJ, Kristensen JH, Paech M et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. *Br J Clin Pharmacol* 1998; 45(5):459-462.
71. Wiles DH, Orr MW, Kolakowska T. Chlorpromazine levels in plasma and milk of nursing mothers. *Br J Clin Pharmacol* 1978; 5(3):272-273.
72. Blacker KH, Weinstein BJ, Ellman G. Mother's milk and chlorpromazine. *Am J Psychiatry* 1962; 119:178-179.
73. Matheson I, Evang A, Overo KF, Syversen G. Presence of chlorprothixene and its metabolites in breast milk. *Eur J Clin Pharmacol* 1984; 27(5):611-613.



74. Yoshida K, Smith B, Craggs M, Kumar R. Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants. *Psychol Med* 1998; 28(1):81-91.
75. Whalley LJ, Blain PG, Prime JK. Haloperidol secreted in breast milk. *Br Med J (Clin Res Ed)* 1981; 282(6278):1746-1747.
76. Stewart RB, Karas B, Springer PK. Haloperidol excretion in human milk. *Am J Psychiatry* 1980; 137(7):849-850.
77. Olesen OV, Bartels U, Poulsen JH. Perphenazine in breast milk and serum. *Am J Psychiatry* 1990; 147(10):1378-1379.
78. Barnas C, Bergant A, Hummer M, Saria A, Fleischhacker WW. Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk. *Am J Psychiatry* 1994; 151(6):945.
79. Croke S, Buist A, Hackett LP, Ilett KF, Norman TR, Burrows GD. Olanzapine excretion in human breast milk: estimation of infant exposure. *Int J Neuropsychopharmacol* 2002; 5(3):243-247.
80. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. *J Clin Psychopharmacol* 2000; 20(4):399-403.
81. Gardiner SJ, Kristensen JH, Begg EJ, Hackett LP, Wilson DA, Ilett KF et al. Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants. *Am J Psychiatry* 2003; 160(8):1428-1431.
82. Hill RC, McIvor RJ, Wojnar-Horton RE, Hackett LP, Ilett KF. Risperidone distribution and excretion into human milk: case report and estimated infant exposure during breastfeeding. *J Clin Psychopharmacol* 2000; 20(2):285-286.
83. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. *Am J Obstet Gynecol* 1993; 168(5):1393-1399.
84. Anderson PO, McGuire GG. Neonatal alprazolam withdrawal--possible effects of breast feeding. *DICP* 1989; 23(7-8):614.
85. Soderman P, Matheson I. Clonazepam in breast milk. *Eur J Pediatr* 1988; 147(2):212-213.
86. Fisher JB, Edgren BE, Mammel MC, Coleman JM. Neonatal apnea associated with maternal clonazepam therapy: a case report. *Obstet Gynecol* 1985; 66(3 Suppl):34S-35S.
87. Brandt R. Passage of diazepam and desmethyldiazepam into breast milk. *Arzneimittelforschung* 1976; 26(3):454-457.
88. Erkkola R, Kanto J. Diazepam and breastfeeding. *Lancet* 1972; 1(7762):1235-1236.
89. Patrick MJ, Tilstone WJ, Reavey P. Diazepam and breastfeeding. *Lancet* 1972; 1(7749):542-543.
90. Wesson DR, Camber S, Harkey M, Smith DE. Diazepam and desmethyldiazepam in breast milk. *J Psychoactive Drugs* 1985; 17(1):55-56.
91. Cole AP, Hailey DM. Diazepam and active metabolite in breast milk and their transfer to the neonate. *Arch Dis Child* 1975; 50(9):741-742.
92. Wretling M. Excretion of oxazepam in breast milk. *Eur J Clin Pharmacol* 1987; 33(2):209-210.
93. Whitelaw AG, Cummings AJ, McFadyen IR. Effect of maternal lorazepam on the neonate. *Br Med J (Clin Res Ed)* 1981; 282(6270):1106-1108.
94. Lebedevs TH, Wojnar-Horton RE, Yapp P, Roberts MJ, Dusci LJ, Hackett LP et al. Excretion of temazepam in breast milk. *Br J Clin Pharmacol* 1992; 33(2):204-206.
95. Frey B, Schubiger G, Musy JP. Transient cholestatic hepatitis in a neonate associated with carbamazepine exposure during pregnancy and breastfeeding. *Eur J Pediatr* 1990; 150(2):136-138.
96. Frey B, Braegger CP, Ghelfi D. Neonatal cholestatic hepatitis from carbamazepine exposure during pregnancy and breast feeding. *Ann Pharmacother* 2002; 36(4):644-647.
97. Merlob P, Mor N, Litwin A. Transient hepatic dysfunction in an infant of an epileptic mother treated with carbamazepine during pregnancy and breastfeeding. *Ann Pharmacother* 1992; 26(12):1563-1565.
98. Wisner KL, Perel JM. Serum levels of valproate and carbamazepine in breastfeeding mother-infant pairs. *J Clin Psychopharmacol* 1998; 18(2):167-169.
99. Schmidt K, Olesen OV, Jensen PN. Citalopram and breastfeeding: serum concentration and side effects in the infant. *Biol Psychiatry* 2000; 47(2):164-165.
100. Froescher W, Eichelbaum M, Niesen M, Dietrich K, Rausch P. Carbamazepine levels in breast milk. *Ther Drug Monit* 1984; 6(3):266-271.
101. Niebyl JR, Blake DA, Freeman JM, Luff RD. Carbamazepine levels in pregnancy and lactation. *Obstet Gynecol* 1979; 53(1):139-140.
102. Pynnonen S, Kanto J, Sillanpaa M, Erkkola R. Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk. *Acta Pharmacol Toxicol (Copenh)* 1977; 41(3):244-253.
103. Pynnonen S, Sillanpaa M. Letter: Carbamazepine and mother's milk. *Lancet* 1975; 2(7934):563.
104. Kok TH, Taitz LS, Bennett MJ, Holt DW. Drowsiness due to clemastine transmitted in breast milk. *Lancet* 1982; 1(8277):914-915.

105. Kuhnz W, Jager-Roman E, Rating D, Deichl A, Kunze J, Helge H et al. Carbamazepine and carbamazepine-10,11- epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. *Pediatr Pharmacol (New York )* 1983; 3(3-4):199-208.
106. Rane A, Tunell R. Ethosuximide in human milk and in plasma of a mother and her nursed infant. *Br J Clin Pharmacol* 1981; 12(6):855-858.
107. Kuhnz W, Koch S, Jakob S, Hartmann A, Helge H, Nau H. Ethosuximide in epileptic women during pregnancy and lactation period. Placental transfer, serum concentrations in nursed infants and clinical status. *Br J Clin Pharmacol* 1984; 18(5):671-677.
108. Koup JR, Rose JQ, Cohen ME. Ethosuximide pharmacokinetics in a pregnant patient and her newborn. *Epilepsia* 1978; 19(6):535-539.
109. Tomson T, Villen T. Ethosuximide enantiomers in pregnancy and lactation. *Ther Drug Monit* 1994; 16(6):621-623.
110. Kuhnz W, Koch S, Helge H, Nau H. Primidone and phenobarbital during lactation period in epileptic women: total and free drug serum levels in the nursed infants and their effects on neonatal behavior. *Dev Pharmacol Ther* 1988; 11(3):147-154.
111. Nau H, Rating D, Hauser I, Jager E, Koch S, Helge H. Placental transfer and pharmacokinetics of primidone and its metabolites phenobarbital, PEMA and hydroxyphenobarbital in neonates and infants of epileptic mothers. *Eur J Clin Pharmacol* 1980; 18(1):31-42.
112. Kaneko S, Sato T, Suzuki K. The levels of anticonvulsants in breast milk. *Br J Clin Pharmacol* 1979; 7(6):624-627.
113. Mirkin BL. Diphenylhydantoin: placental transport, fetal localization, neonatal metabolism, and possible teratogenic effects. *J Pediatr* 1971; 78(2):329-337.
114. Steen B, Rane A, Lonnerholm G, Falk O, Elwin CE, Sjoqvist F. Phenytoin excretion in human breast milk and plasma levels in nursed infants. *Ther Drug Monit* 1982; 4(4):331-334.
115. Finch E, Lorber J. Methaemoglobinaemia in the newborn: probably due to phenytoin excreted in human milk. *J Obstet Gynaecol Br Emp* 1954; 61:833-834.
116. Piontek CM, Baab S, Peindl KS, Wisner KL. Serum valproate levels in 6 breastfeeding mother-infant pairs. *J Clin Psychiatry* 2000; 61(3):170-172.
117. Stahl MM, Neiderud J, Vinge E. Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid. *J Pediatr* 1997; 130(6):1001-1003.
118. Philbert A, Pedersen B, Dam M. Concentration of valproate during pregnancy, in the newborn and in breast milk. *Acta Neurol Scand* 1985; 72(5):460-463.
119. Alexander FW. Sodium valproate and pregnancy. *Arch Dis Child* 1979; 54(3):240.
120. Nau H, Rating D, Koch S, Hauser I, Helge H. Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers. *J Pharmacol Exp Ther* 1981; 219(3):768-777.
121. Tsuru N, Maeda T, Tsuruoka M. Three cases of delivery under sodium valproate--placental transfer, milk transfer and probable teratogenicity of sodium valproate. *Jpn J Psychiatry Neurol* 1988; 42(1):89-96.
122. von Unruh GE, Froescher W, Hoffmann F, Niesen M. Valproic acid in breast milk: how much is really there? *Ther Drug Monit* 1984; 6(3):272-276.
123. Dickinson RG, Harland RC, Lynn RK, Smith WB, Gerber N. Transmission of valproic acid (Depakene) across the placenta: half-life of the drug in mother and baby. *J Pediatr* 1979; 94(5):832-835.
124. Hale TW. *Medications and Mothers' Milk*. Tenth ed. 2002.
125. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. *Epilepsia* 2000; 41(6):709-713.
126. Tomson T, Ohman I, Vitols S. Lamotrigine in pregnancy and lactation: a case report. *Epilepsia* 1997; 38(9):1039-1041.
127. Rambeck B, Kurlemann G, Stodieck SR, May TW, Jurgens U. Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. *Eur J Clin Pharmacol* 1997; 51(6):481-484.
128. Ohman I, Vitols S, Luef G, Soderfeldt B, Tomson T. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. *Epilepsia* 2002; 43(10):1157-1160.
129. Tran A, O'Mahoney T, Rey E, Mai J, Mumford JP, Olive G. Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers. *Br J Clin Pharmacol* 1998; 45(4):409-411.